Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Larimar Therapeutics, Inc.ZFGN · Entity 5634 | Chief Business Officer | January 22, 2019 | January 24, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Larimar Therapeutics, Inc.
Report date January 22, 2019 · Filed January 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.63 · Expires 2029-01-22 | Direct | 125,000 |
Reported balance
After 2019-01-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-22 · Grant · Acquired 125,000 · Balance 125,000 F1: 25% of this option vests on January 22, 2020, and the remainder vests in equal monthly installments thereafter over 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option vests on January 22, 2020, and the remainder vests in equal monthly installments thereafter over 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2019 Filed Jan 24, 2019 20:25 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0000899243-19-001928 · doc4.xml · derivative · entry 1 McVeigh Brian · CIK 0001742110 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2029-01-22 F1 · derivative.exercise_date: 25% of this option vests on January 22, 2020, and the remainder vests in equal monthly installments thereafter over 36 months. Read SEC document |
| May 29, 2018 Filed May 30, 2018 17:32 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0000899243-18-014478 · doc4.xml · derivative · entry 1 McVeigh Brian · CIK 0001742110 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2028-05-29 F1 · derivative.exercise_date: 25% of this option vests on May 29, 2019 and the remainder vests in equal monthly installments thereafter over a 3-year period. The option has been granted pursuant to an inducement award agreement outside of the company's 2014 Stock Option and Incentive Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4). The option is subject to acceleration upon a change in control pursuant to the terms of the reporting person's Severance and Change in Control Agreement dated as of May 29, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.